標(biāo)題: Titlebook: Antifolate Drugs in Cancer Therapy; Ann L. Jackman Book 1999 Springer Science+Business Media New York 1999 biochemistry.cancer.cancer ther [打印本頁(yè)] 作者: MEDAL 時(shí)間: 2025-3-21 18:19
書(shū)目名稱Antifolate Drugs in Cancer Therapy影響因子(影響力)
書(shū)目名稱Antifolate Drugs in Cancer Therapy影響因子(影響力)學(xué)科排名
書(shū)目名稱Antifolate Drugs in Cancer Therapy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Antifolate Drugs in Cancer Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Antifolate Drugs in Cancer Therapy被引頻次
書(shū)目名稱Antifolate Drugs in Cancer Therapy被引頻次學(xué)科排名
書(shū)目名稱Antifolate Drugs in Cancer Therapy年度引用
書(shū)目名稱Antifolate Drugs in Cancer Therapy年度引用學(xué)科排名
書(shū)目名稱Antifolate Drugs in Cancer Therapy讀者反饋
書(shū)目名稱Antifolate Drugs in Cancer Therapy讀者反饋學(xué)科排名
作者: drusen 時(shí)間: 2025-3-21 22:36
Ekphrasis and the Polytemporal in w antifolate drugs approved for marketing: trimetrexate (Neutrexin), a lipophilic inhibitor of dihydrofolate reductase (DHFR) for treatment of the life-threatening fungal infection, . pneumonia; and the thymidylate synthase (TS) inhibitor, raltitrexed (Tomudex), for colorectal cancer. In addition to作者: expeditious 時(shí)間: 2025-3-22 04:25
https://doi.org/10.1057/9780230370531s of folate metabolism, alterations in the activity of any folate enzyme, cellular transport system, as well as the concentration of any folate metabolite may be relevant to antifolate cytotoxicity and selectivity. Therefore, it is difficult to predict the results of inhibiting a given folate enzyme作者: 軍火 時(shí)間: 2025-3-22 08:15 作者: 尖叫 時(shí)間: 2025-3-22 10:40
Die Prurigoformen flüchtigeren CharaktersTX, .) were found to induce temporary remission in children with acute leukemia .. In the five decades that followed this landmark in the history of chemotherapy ., the term “an-tifolate” or “antifol” has come to refer not only to inhibitors of DHFR but also to in-hibitors of other enzymes of one-ca作者: 一個(gè)攪動(dòng)不安 時(shí)間: 2025-3-22 13:15
Die Prurigoformen flüchtigeren Charaktersombination with other agents for the treatment of various types of cancer . such as cancers of the gas-trointestinal tract, breast cancer, and head and neck cancer. For combinations of leucov-orin (LV) and 5FU objective response rates between 20 and 40% have been achieved in randomized trials in pat作者: STALL 時(shí)間: 2025-3-22 18:25 作者: HIKE 時(shí)間: 2025-3-22 23:17 作者: Hot-Flash 時(shí)間: 2025-3-23 02:51 作者: 為敵 時(shí)間: 2025-3-23 06:43
C. Guillén,M. C. Romero,I. Galindote moieties in vivo. However, unlike some other TS inhibitors and other antifolates, the TS inhibition constant and noncompetitive mode of inhibition is unaffected by polyglutamation. The compound is readily transported on the reduced folate carrier, and accumulates in cells. The main cellular metab作者: RUPT 時(shí)間: 2025-3-23 13:14
C. Guillén,M. C. Romero,I. Galindoriority to evaluate drugs that may possess either greater efficacy or activity in tumors with intrinsic or acquired resistance to established treatment. Nolatrexed dihydrochloride (Thymitaq.) is a novel folate-based inhibitor of thymidylate synthase (TS). TS is the rate-limiting enzyme in the . bios作者: Connotation 時(shí)間: 2025-3-23 15:52
https://doi.org/10.1007/978-3-031-35135-8nce DNA synthesis, has been achieved with a range of quinazoline analogs of folic acid, including CB3717 (.–.) and its non-nephrotoxic successor, Tomudex. (ZD1694, raltitrexed) (.–.). The latter compound has recently been introduced in a number of counties for the treatment of advanced colorectal ca作者: Rejuvenate 時(shí)間: 2025-3-23 20:59 作者: Flat-Feet 時(shí)間: 2025-3-23 23:42
C. Guillén,M. C. Romero,I. Galindo glycinamide ribonucleotide formyltransferase (GARFT). Lometrexol was a landmark anticancer compound for a number of reasons: it was the first potent and selective GARFT inhibitor, it had in vivo antitumor activity in models in which earlier classes of antifolate drugs were inactive (.) and it was, 作者: preeclampsia 時(shí)間: 2025-3-24 06:16
Javier Dóniz-Páez,Rafael Becerra-Ramírezidylate, purines, and amino acids (.).For this reason, cellular folate homeostasis depends on the delivery of reduced folate cofactors from extracellular fluids. At a physiological pH, the negatively charged α- and γ-carboxyl groups of the glutamate side chain of reduced folate cofactors change thes作者: placebo-effect 時(shí)間: 2025-3-24 06:50
https://doi.org/10.1007/978-3-031-07289-5in hematopoietic cells and intestinal mucosa, with lesser effects on kidney, liver, and the central nervous system (.). An accepted strategy to overcome these toxicities is the supplementation of folates as rescue agents (.–.). In this context, the use of high doses of methotrexate (MTX) with leucov作者: 禁止 時(shí)間: 2025-3-24 13:05
Disaster Studies and Management, methionine, purines, and thymidylate. Across the phylogenetic spectrum, intracellular folates consist almost entirely of poly (γ-glutamyl) metabolites (Fig. 1; reviewed in refs. .–.). A distribution of lengths generally occurs that is cell type-specific; within a given source the distribution is g作者: 前兆 時(shí)間: 2025-3-24 18:46
Asim Zia,Mujahid Hussain,Kashif Hameedcally in the late 1960s, in diseases such as leukemia and lymphoma. The basic principle in selection of these combinations was simple; drugs that were effective as single agents but had nonoverlapping normal tissue toxicity were chosen (e.g., vincristine and prednisone). If drugs had similar toxicit作者: maverick 時(shí)間: 2025-3-24 20:35
Asim Zia,Mujahid Hussain,Kashif Hameedacil remains one of the most active agents in the treatment of diseases such as colorectal, breast, and head and neck cancer. Attempts to biomodulate the activity of 5-fluorouracil have focused primarily on enhancing its ability to inhibit the target enzyme thymidylate synthase which is essential fo作者: Epithelium 時(shí)間: 2025-3-25 00:27 作者: FLING 時(shí)間: 2025-3-25 06:42
https://doi.org/10.1007/978-1-59259-725-3biochemistry; cancer; cancer therapy; cell; cell death; chemotherapy; drug; drugs; future; genomics; immunothe作者: 和藹 時(shí)間: 2025-3-25 10:38
978-1-4757-4521-4Springer Science+Business Media New York 1999作者: FRAX-tool 時(shí)間: 2025-3-25 15:40 作者: 機(jī)械 時(shí)間: 2025-3-25 19:09
2196-9906 cell death. ..The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics. ..978-1-4757-4521-4978-1-59259-725-3Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: Jacket 時(shí)間: 2025-3-25 22:54
Ekphrasis and the Polytemporal in logy that have sparked major debates over the years. Several of these areas will be dealt with very briefly, because they are covered in more detail in subsequent chapters. The final section touches on some unanswered questions, which are areas of current debate, and which are likely to be the focus作者: 窗簾等 時(shí)間: 2025-3-26 00:59
https://doi.org/10.1057/9780230370531r et al. . in 1948. This work depended on knowledge generated at the American Cyanamid Company, Pearl River, NY, on the structure of folic acid and the chemical synthesis of analogs in addition to the insightful clinical observations of the Farber group .. This work was done before the role of tetra作者: 消耗 時(shí)間: 2025-3-26 05:55
https://doi.org/10.1007/978-3-662-28804-7f knowledge for the development of the antifolate thymidylate synthase (TS) inhibitors over the last 20 yr (. Chapter 1). For example, it was shown that the cytotoxicity induced by the indirect inhibition of TS by MTX may be antagonized by its inhibitory effects on . purine synthesis .. The antipuri作者: ANTE 時(shí)間: 2025-3-26 10:38 作者: white-matter 時(shí)間: 2025-3-26 14:37
C. Guillén,M. C. Romero,I. GalindoThe folate-based cytotoxic agents are more likely, when compared with their pyrimidine-based counterparts, to have a unique locus of action, not be incorporated into nucleic acids, and not be susceptible to catabolic degradation. The first clinically evaluable folate-based TS inhibitor was CB3717. T作者: AER 時(shí)間: 2025-3-26 18:24
https://doi.org/10.1007/978-3-031-35135-8f more recent interest has been the development of water-soluble acidic, quinazoline-based TS inhibitors that lack FPGS substrate activity but retain high affmity for the RFC. Work from the group of F. Sirotnak (.) has provided evidence that compounds with favorable kinetic parameters for the RFC ma作者: adjacent 時(shí)間: 2025-3-26 23:16
C. Guillén,M. C. Romero,I. Galindo 5′-thienyl-dideazatetrahydrofolic acid), which is more potent than lometrexol and has greater antitumor efficacy in vivo (2). Biochemical and pharmacological differences between LY309887 and lometrexol with respect to potency to inhibit GARFT, differential transport and storage in liver, and polygl作者: BUCK 時(shí)間: 2025-3-27 05:12 作者: 詳細(xì)目錄 時(shí)間: 2025-3-27 08:40
Javier Dóniz-Páez,Rafael Becerra-Ramírezreductase (DHFR) (.). More recently, folate analogs were synthesized that could target other key enzymes in folate metabolism, including thymidylate synthase (TS) (., .) glycinamide ribonucleotide transformylase (GARTFase) (., .) and folylpolyglutamate synthetase (FPGS) (.). A number of these novel 作者: 必死 時(shí)間: 2025-3-27 13:09
https://doi.org/10.1007/978-3-031-07289-5ity in several epithelial malignancies (.–.). The rational use of folates as modulators of toxicity or antitumor activity requires an integral understanding of their biochemistry, pharmacokinetics, and pharmacodynamics.作者: PRO 時(shí)間: 2025-3-27 17:33 作者: 關(guān)節(jié)炎 時(shí)間: 2025-3-27 21:18
Folate Biochemistry in Relation to Antifolate Selectivity,r et al. . in 1948. This work depended on knowledge generated at the American Cyanamid Company, Pearl River, NY, on the structure of folic acid and the chemical synthesis of analogs in addition to the insightful clinical observations of the Farber group .. This work was done before the role of tetra作者: legitimate 時(shí)間: 2025-3-27 23:02
Raltitrexed (TomudexTM), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor,f knowledge for the development of the antifolate thymidylate synthase (TS) inhibitors over the last 20 yr (. Chapter 1). For example, it was shown that the cytotoxicity induced by the indirect inhibition of TS by MTX may be antagonized by its inhibitory effects on . purine synthesis .. The antipuri作者: 有其法作用 時(shí)間: 2025-3-28 02:09 作者: 泥沼 時(shí)間: 2025-3-28 07:19
Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed DihydrochThe folate-based cytotoxic agents are more likely, when compared with their pyrimidine-based counterparts, to have a unique locus of action, not be incorporated into nucleic acids, and not be susceptible to catabolic degradation. The first clinically evaluable folate-based TS inhibitor was CB3717. T作者: Hearten 時(shí)間: 2025-3-28 14:01
ZD9331,f more recent interest has been the development of water-soluble acidic, quinazoline-based TS inhibitors that lack FPGS substrate activity but retain high affmity for the RFC. Work from the group of F. Sirotnak (.) has provided evidence that compounds with favorable kinetic parameters for the RFC ma作者: 使成波狀 時(shí)間: 2025-3-28 18:26 作者: 弄污 時(shí)間: 2025-3-28 21:58 作者: 興奮過(guò)度 時(shí)間: 2025-3-29 02:42
Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates,reductase (DHFR) (.). More recently, folate analogs were synthesized that could target other key enzymes in folate metabolism, including thymidylate synthase (TS) (., .) glycinamide ribonucleotide transformylase (GARTFase) (., .) and folylpolyglutamate synthetase (FPGS) (.). A number of these novel 作者: 大火 時(shí)間: 2025-3-29 04:18
Folates as Chemotherapeutic Modulators,ity in several epithelial malignancies (.–.). The rational use of folates as modulators of toxicity or antitumor activity requires an integral understanding of their biochemistry, pharmacokinetics, and pharmacodynamics.作者: Intellectual 時(shí)間: 2025-3-29 07:20 作者: 多骨 時(shí)間: 2025-3-29 12:36
Folate Biochemistry in Relation to Antifolate Selectivity,s of folate metabolism, alterations in the activity of any folate enzyme, cellular transport system, as well as the concentration of any folate metabolite may be relevant to antifolate cytotoxicity and selectivity. Therefore, it is difficult to predict the results of inhibiting a given folate enzyme作者: CLASH 時(shí)間: 2025-3-29 18:17
Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors,LL), was first tested .. Methotrexate (MTX), also an antifolate inhibitor of dihydrofolate reductase (DHFR), soon after replaced aminopterin in the clinic and is used widely not only for the treatment of various forms of cancer, such as lymphoma, germ-cell tumors, breast cancer, and head and neck ca作者: Vertical 時(shí)間: 2025-3-29 22:01
Development of Nonpolyglutamatable DHFR Inhibitors,TX, .) were found to induce temporary remission in children with acute leukemia .. In the five decades that followed this landmark in the history of chemotherapy ., the term “an-tifolate” or “antifol” has come to refer not only to inhibitors of DHFR but also to in-hibitors of other enzymes of one-ca作者: 文藝 時(shí)間: 2025-3-30 01:30
Fluoropyrimidines as Antifolate Drugs,ombination with other agents for the treatment of various types of cancer . such as cancers of the gas-trointestinal tract, breast cancer, and head and neck cancer. For combinations of leucov-orin (LV) and 5FU objective response rates between 20 and 40% have been achieved in randomized trials in pat作者: Lime石灰 時(shí)間: 2025-3-30 06:58 作者: 蚊子 時(shí)間: 2025-3-30 11:15
Tomudex,er drug that owes its cytotoxicity to inhibition of the enzyme thymidylate synthase (TS). TS catalyzes the reductive methylation of deoxyuridylate monophosphate (dUMP) to thymidylate (TMP), the rate-limiting step in the . synthesis of thymidine triphosphate (TTP), the only nucleotide specific for DN作者: 不持續(xù)就爆 時(shí)間: 2025-3-30 16:05
Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, agents for the management of neoplastic diseases. However, it was only in the last 10–15 yr, because of the rapid advances of medicinal chemistry, X-ray protein crystallography, molecular biology, pharmacology, and clinical medicine, that a significant number of new generation antifolates were brou作者: FRAX-tool 時(shí)間: 2025-3-30 18:12
GW1843,te moieties in vivo. However, unlike some other TS inhibitors and other antifolates, the TS inhibition constant and noncompetitive mode of inhibition is unaffected by polyglutamation. The compound is readily transported on the reduced folate carrier, and accumulates in cells. The main cellular metab作者: 確定方向 時(shí)間: 2025-3-31 00:33
Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochriority to evaluate drugs that may possess either greater efficacy or activity in tumors with intrinsic or acquired resistance to established treatment. Nolatrexed dihydrochloride (Thymitaq.) is a novel folate-based inhibitor of thymidylate synthase (TS). TS is the rate-limiting enzyme in the . bios作者: 臆斷 時(shí)間: 2025-3-31 02:20
ZD9331,nce DNA synthesis, has been achieved with a range of quinazoline analogs of folic acid, including CB3717 (.–.) and its non-nephrotoxic successor, Tomudex. (ZD1694, raltitrexed) (.–.). The latter compound has recently been introduced in a number of counties for the treatment of advanced colorectal ca作者: catagen 時(shí)間: 2025-3-31 05:33
Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors ycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme in this pathway, might have utility in the treatment of cancer. In 1987, clinical investigations were initiated with lometrexol (6R-dideazatetrahydrofolic acid, 6R-DDATHF), a novel “tight-binding” inhibitor of GARF作者: Memorial 時(shí)間: 2025-3-31 12:00 作者: 抗原 時(shí)間: 2025-3-31 13:46 作者: 繼而發(fā)生 時(shí)間: 2025-3-31 19:40
Folates as Chemotherapeutic Modulators,in hematopoietic cells and intestinal mucosa, with lesser effects on kidney, liver, and the central nervous system (.). An accepted strategy to overcome these toxicities is the supplementation of folates as rescue agents (.–.). In this context, the use of high doses of methotrexate (MTX) with leucov作者: Antigen 時(shí)間: 2025-4-1 00:36 作者: 未開(kāi)化 時(shí)間: 2025-4-1 01:59 作者: farewell 時(shí)間: 2025-4-1 07:30 作者: Watemelon 時(shí)間: 2025-4-1 10:49 作者: Abduct 時(shí)間: 2025-4-1 16:42
Die Prurigoformen flüchtigeren Charaktersents have an intrinsic resistance to 5FU, and since almost all patients will show a relapse, this means that in the remaining tumors acquired resistance will occur. Unfortunately the mechanism of modulation-re-sistance has hardly been addressed in most of these studies.作者: 知道 時(shí)間: 2025-4-1 21:46
